HCPC
VRTX icon

Hamilton Capital Partners (Canada)’s Vertex Pharmaceuticals VRTX Stock Holding History

Hamilton Capital Partners (Canada)’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.16M Buy
16,419
+2,366
+17% +$1.05M 0.24% 74
2026
Q1 		$6.28M Sell
14,053
-167
-1% -$77.9K 0.21% 83
2025
Q4 		$6.45M Buy
14,220
+1,891
+15% +$815K 0.24% 77
2025
Q3 		$4.83M Buy
12,329
+2,813
+30% +$1.18M 0.2% 90
2025
Q2 		$4.24M Buy
9,516
+1,742
+22% +$803K 0.22% 91
2025
Q1 		$3.77M Sell
7,774
-337
-4% -$157K 0.24% 93
2024
Q4 		$3.27M Sell
8,111
-1,334
-14% -$618K 0.24% 87
2024
Q3 		$4.39M Sell
9,445
-1,101
-10% -$529K 0.38% 64
2024
Q2 		$4.94M Sell
10,546
-154
-1% -$66.8K 0.53% 58
2024
Q1 		$4.47M Buy
+10,700
New +$4.52M 0.54% 65

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Hamilton Capital Partners (Canada)'s VRTX Position: Q2 2026 in Review

Hamilton Capital Partners (Canada) increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, buying an estimated $1.05M and bringing the position to 16,419 shares worth $8.16M. The position accounts for 0.24% of the portfolio, ranked #74.

Hamilton Capital Partners (Canada) first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. 1,663 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Hamilton Capital Partners (Canada) held 16,419 shares of Vertex Pharmaceuticals worth $8.16M as of Q2 2026.
  • Hamilton Capital Partners (Canada) bought 2,366 Vertex Pharmaceuticals shares in Q2 2026, an estimated $1.05M.
  • Vertex Pharmaceuticals made up 0.24% of Hamilton Capital Partners (Canada)'s portfolio in Q2 2026, its #74 holding.
  • Hamilton Capital Partners (Canada) first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 1,663 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Hamilton Capital Partners (Canada)'s 13F filing for Q2 2026, filed 14 Aug 2026.